The peripheral vascular devices market encompasses the medical technology sector focused on tools and implants used to diagnose and treat conditions affecting blood vessels outside the heart and brain. It primarily serves individuals with vascular diseases such as peripheral artery disease and deep vein thrombosis to restore proper blood flow and manage blockages through minimally invasive procedures.
The global peripheral vascular devices market was valued at USD 9.55 billion in 2025 and USD 10.02 billion in 2026, and it is projected to reach USD 13.22 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.7%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=790
The peripheral vascular industry market is primarily driven by the escalating global prevalence of peripheral artery disease (PAD) linked to aging populations, sedentary lifestyles, and rising rates of diabetes and obesity, alongside a strong consumer and clinical preference for minimally invasive endovascular procedures. However, market expansion is heavily restrained by the high cost of advanced cutting-edge devices, complex reimbursement frameworks, and competition from alternative treatments like traditional pharmacological and supervised exercise therapies. Lucrative opportunities exist in the high growth potential of emerging markets experiencing rapid healthcare infrastructure improvements, as well as the ongoing development of innovative products like next-generation drug-coated balloons, bioresorbable scaffolds, and AI-enabled imaging technologies. Despite these prospects, the market faces critical challenges, including strict regulatory scrutiny and long approval timelines, high clinical trial costs, severe pricing pressures from institutional group purchasing systems, and supply chain vulnerabilities regarding specialized raw materials and device components.
The target customers for the peripheral vascular industry market primarily encompass clinical healthcare providers, including public and private hospitals, specialized vascular clinics, cardiac catheterization labs, and rapidly expanding ambulatory surgical centers (ASCs), who treat a large geriatric patient demographic suffering from peripheral artery disease, diabetes, and other circulatory disorders. These institutional buyers need highly reliable, low-risk, and safe interventional devices—such as peripheral stents, angioplasty balloons, catheters, and atherectomy systems—that facilitate faster patient recovery times, compress hospital stays, and effectively manage complex or calcium-heavy lesions. Providers demonstrate a strong preference for minimally invasive endovascular alternatives over traditional open surgeries to reduce procedural complications and overall operational costs, while increasingly favoring advanced innovations like drug-coated balloons and next-generation resorbable scaffolds that offer established long-term clinical patency. Their purchasing behavior is heavily dictated by shifting healthcare delivery models, favorable regional insurance reimbursement mechanisms, and tightening institutional budgets, which drive intense vendor price competition, direct-to-manufacturer contracting, and an accelerating migration of routine device procurement toward cost-effective outpatient and ASC facilities.
Market entry, expansion, and profitability in the peripheral vascular devices market are heavily shaped by a complex blend of regulatory frameworks, rapid technological innovation, and distinct economic pressures. Regulatory environments enforce stringent safety scrutiny and approval pathways, such as extensive clinical trial data required by the FDA that can extend device vetting times to 3–7 years, which elevates financial risks for new entrants while providing essential public confidence. On the technological front, the market is being disrupted by continuous advancements in drug-coated balloons, drug-eluting stents, bioresorbable vascular scaffolds, and AI-enabled imaging-guided delivery systems that improve long-term patency and clinical outcomes. Economically, while an aging global population and a rising burden of peripheral artery disease ensure robust demand, long-term profitability faces critical challenges from the high upfront costs of advanced devices, stringent pricing caps, and bundled-payment rules that compress profit margins as interventional workflows migrate toward ambulatory surgical centers and office-based labs.
The peripheral vascular industry market is being significantly shaped by a rapid clinical transition from traditional open bypass surgeries toward minimally invasive endovascular procedures, utilizing advanced catheter-based therapies, drug-eluting stents, and drug-coated balloons to improve patient recovery times and long-term patency. A major emerging trend is the accelerating adoption of plaque-modification technologies, particularly atherectomy systems to treat calcified lesions, supported by favorable international reimbursement shifts. Concurrently, there is a prominent operational migration of low-complexity interventions away from inpatient hospital suites into outpatient settings like ambulatory surgical centers (ASCs) and office-based labs. These trends are evolving swiftly, as evidenced by a 47% surge in percutaneous interventions contrasting with a 31% decline in open surgeries over a recent ten-year period, while specialized segments like atherectomy devices and ASC procurement are outpacing the broader market with robust projected compound annual growth rates (CAGRs) of 8.22% and over 7% respectively through 2031.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=790
Technological innovations disrupting the peripheral vascular industry market are centered on advancing minimally invasive endovascular therapies, enhancing precision, and moving toward temporary structural support. The industry is seeing significant traction in next-generation drug-coated balloons (DCBs) and drug-eluting stents (DES) that utilize refined antiproliferative coatings to minimize restenosis without leaving permanent metal implants. Furthermore, bioresorbable scaffolds (BRS) are gaining rapid adoption as a “disappearing” solution that supports the vessel wall during healing before naturally dissolving into the body. This material shift is heavily complemented by the integration of artificial intelligence for predictive imaging and real-time hemodynamic analysis, alongside the expanding adoption of robotic-assisted endovascular systems that elevate catheter stability and precision while reducing radiation exposure for clinical teams.
In the peripheral vascular industry market, short-term hype is primarily visible around early-stage, completely non-invasive optical tracking concepts and intensive social media promotions for consumer wellness and generic fitness tracking, which often outpace current clinical reliability and regulatory approvals. Conversely, long-term structural shifts are firmly anchored in medical-grade infrastructure and precision health management. These enduring transformations include a clinical migration of low-complexity procedures from inpatient suites to ambulatory surgical centers (ASCs) and office-based labs (OBLs), a profound technological transition toward less-invasive endovascular procedures like balloon angioplasty and atherectomy systems that improve patient recovery times, and expanding global healthcare infrastructure across emerging economies to manage the rising institutional burden of peripheral artery disease (PAD) driven by an aging population and increasing rates of diabetes and obesity.
